CICC: Maintains "Outperform Industry" rating on ANGELALIGN (06699) and raises target price to HKD 104.0.

CICC released a research report stating that it maintains ANGELALIGN's (06699) net profit forecast of $32 million for 2026 and $37 million for 2027. The firm retains an "Outperform" rating, but considering the company's growth trends both domestically and internationally, it has raised the target price based on DCF by 22.4% to HKD 104.0, which represents a 30.2% upside from the current stock price. CICC's main points are as follows: Case numbers increased by 40.2% year-on-year in the first half of the year. On July 31, the company forecasted its performance for the first half of 2026: total revenue is expected to be approximately $229.0 to $231.0 million, an increase of 41.9% to 43.1% year-on-year; net profit is expected to be approximately $24.0 to $25.4 million, an increase of 69.0% to 78.9% year-on-year, with a total of around 316,600 invisible orthodontic cases, up 40.2% year-on-year. The number of cases slightly exceeded market expectations, primarily due to continuous sales growth both domestically and internationally, while net profit slightly surpassed expectations mainly due to increased economies of scale. Consolidating competitive advantages in the domestic market. According to the companys announcement, for the first half of 2026, the number of cases in the mainland Chinese market grew by approximately 36.8% to about 148,600 cases. The firm believes this slightly exceeds market expectations, primarily due to increasing emphasis by doctors in China's lower-tier markets on professional reputation and patient experience, leading to a shift towards stable and effective professional products and services like ANGELALIGN. The firm believes the company is likely to continue actively seizing growth opportunities in China's lower-tier markets. Significant results from overseas professional brand investment. According to the companys announcement, in the first half of 2026, the number of cases in the global market (excluding mainland China) grew by 43.3% to approximately 168,000 cases. Following several years of building a global direct sales network, local customer service systems, and clinical support platforms, the firm believes the company's global operational system has become increasingly robust. According to the companys announcement, it will adhere to a direct service development model for end dentists, continuously strengthening local clinical support, customer service, and doctor education systems in various countries, while gradually withdrawing from low-commitment and low pricing power OEM and commercial channel businesses. Shifting to clinically effective invisible orthodontic systems. The firm believes that the number of cases in the global market is continuing to grow rapidly, mainly due to the increasing influence of the companys professional brand and recognition among doctors, with customer Net Promoter Score (NPS) remaining high. Additionally, according to the companys announcement, leveraging an open management culture and a multinational talent team, it has integrated the strengths of multiple countries to achieve deep collaboration, thereby accelerating the company's innovation pace in the fields of medical products, medical software, and medical services. Risk warning: risks of failed R&D, risks of worsening competitive landscape, and overseas business risks.